The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...

Sheffield-headquartered aquaculture biotechnology company, Benchmark, has agreed to sell its genetics business area to Novo ...

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...

BRUSSELS/LONDON, Nov 22 (Reuters) - Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent (CTLT.N), opens new ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

EU antitrust regulators on Friday closed a four-year long investigation into Apple's rules for competing e-book and audiobook ...

Quanta Dialysis Technologies has raised $60 million to expand its U.S. commercial presence for its Quanta dialysis system.